Ekso Bionics (NASDAQ:EKSO) Director Steven Sherman bought 200,000 shares of the business’s stock in a transaction on Wednesday, May 23rd. The stock was purchased at an average price of $1.51 per share, for a total transaction of $302,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ekso Bionics traded up $0.02, hitting $1.52, during trading on Friday, according to Marketbeat Ratings. The stock had a trading volume of 120,559 shares, compared to its average volume of 339,177. The stock has a market capitalization of $90.53 million, a price-to-earnings ratio of -1.71 and a beta of -0.63. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.50 and a current ratio of 2.79. Ekso Bionics has a 12 month low of $0.99 and a 12 month high of $4.77.
Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Tuesday, March 13th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.05). The firm had revenue of $2.45 million during the quarter. Ekso Bionics had a negative net margin of 340.49% and a negative return on equity of 184.66%. equities research analysts forecast that Ekso Bionics will post -0.48 EPS for the current year.
Several large investors have recently bought and sold shares of EKSO. BlackRock Inc. increased its position in shares of Ekso Bionics by 97.3% during the 4th quarter. BlackRock Inc. now owns 110,840 shares of the company’s stock worth $236,000 after purchasing an additional 54,663 shares during the last quarter. Advisor Group Inc. increased its position in shares of Ekso Bionics by 3,586.7% during the 4th quarter. Advisor Group Inc. now owns 114,324 shares of the company’s stock worth $244,000 after purchasing an additional 111,223 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Ekso Bionics by 68.6% during the 4th quarter. Geode Capital Management LLC now owns 233,301 shares of the company’s stock worth $496,000 after purchasing an additional 94,923 shares during the last quarter. 38.87% of the stock is currently owned by hedge funds and other institutional investors.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.